Prediction of Response to PD-L1 Inhibitor After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer Using Multi-omics-based Liquid Biopsy

This study aims to explore the efficacy and safety of immunotherapy (PD-L1 inhibitor) maintenance following high-dose hyperfractionated simultaneous integrated boost radiotherapy concurrent chemotherapy in patients with limited-stage small cell lung cancer (LS-SCLC). This study is a prospective observational study. Additionally, liquid biopsy technology will be employed to identify biomarkers that can predict the efficacy of PD-L1 inhibitor after chemoradiotherapy in LS-SCLC.

NCT Number	NCT06869239
Lead Sponsor	Peking University Cancer Hospital & Institute
Conditions	Limited-stage Small Cell Lung Cancer (LS-SCLC)
Enrollment	65 participants
Start Date	2025-02-25
Primary Completion	2027-01-03 (estimated)
Study Completion	2028-01-03 (estimated)
Updated on ClinicalTrials.gov	2025-03-11